Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy By Ogkologos - February 19, 2026 151 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the marginal zone lymphoma cohort of the TRANSCEND FL study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Clinical Trials in Genitourinary Cancers: TALAPRO-2, KEYNOTE-905, and COSMIC-313 July 9, 2020 How My Cancer Diagnosis Has Fueled My Work in Improving Access... December 19, 2023 FDA Approves Idecabtagene Vicleucel for Multiple Myeloma April 7, 2021 Targeted Therapy Based on Molecular Profiling of Malignant Mesothelioma Tumours Is... October 19, 2020 Load more HOT NEWS Breast Cancer Patient Fights To Have Mastectomy During COVID-19 Restrictions And... FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate... Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC... Cancer in My Community: The 3 Ways People Access Cancer Care...
